Sales warning slams Ozempic maker Novo Nordisk's stock

In afternoon trading the stock was down 18 percent at around 302 kronor ($34) on the Copenhagen stock exchange. The decline has wiped nearly $32 billion off the market value since Tuesday for Novo Nordisk, one of Europe's biggest companies by capitalisation. On Tuesday the company said 2025 sales had risen six percent to 309 billion kronor ($48.9 billion), below the eight to 11 percent gain it had forecast as recently as November. It also said it expected sales to slide by up to 13 percent this...